Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

Core Viewpoint - Revive Therapeutics Ltd. is proposing a private placement offering of up to 30,952,381 units at a price of $0.021 per unit, aiming for gross proceeds of up to $650,000, while also settling a note payable of $67,400 through the issuance of additional units at the same price [1][3]. Group 1: Private Placement Details - The private placement will consist of units, each comprising one common share and one common share purchase warrant, with warrants allowing the purchase of one common share at an exercise price of $0.05 for 36 months post-closing [2]. - The gross proceeds from the offering will be allocated for working capital and settling certain trade payables, with the potential for the placement to close in multiple tranches [3]. Group 2: Closing Conditions and Securities - The closing of the private placement and debt settlement is subject to customary closing conditions, with the company intending to close as soon as practicable [4]. - All securities issued will be subject to a hold period of four months and one day from the issuance date [4]. Group 3: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, prioritizing its drug development pipeline to leverage FDA regulatory incentives for rapid advancement and market entry [5]. - Current efforts are concentrated on the potential of Bucillamine for infectious diseases and medical countermeasures, alongside advancing Psilocybin and molecular hydrogen therapeutic programs [5].